US20030100574A1 - Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies - Google Patents

Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies Download PDF

Info

Publication number
US20030100574A1
US20030100574A1 US10/294,288 US29428802A US2003100574A1 US 20030100574 A1 US20030100574 A1 US 20030100574A1 US 29428802 A US29428802 A US 29428802A US 2003100574 A1 US2003100574 A1 US 2003100574A1
Authority
US
United States
Prior art keywords
gonyautoxin
composition
mixture
saxitoxin
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/294,288
Inventor
Nestor Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytotox SA
Original Assignee
Phytotox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytotox SA filed Critical Phytotox SA
Assigned to PHYTOTOX S.A. reassignment PHYTOTOX S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WILSON, NESTOR ANTONIO LAGOS
Publication of US20030100574A1 publication Critical patent/US20030100574A1/en
Priority to US11/338,156 priority Critical patent/US20060122200A1/en
Priority to US13/487,722 priority patent/US9301958B2/en
Priority to US14/043,634 priority patent/US8889681B2/en
Priority to US14/249,914 priority patent/US8871763B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to pharmaceutical compositions containing heterocyclic guanidine-type compounds and uses thereof for blocking neuronal transmission. More specifically, this invention relates to tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission.
  • Botulin A toxin is a neurotoxin that acts by chemiodenervation, or blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralysing the muscle and preventing its contraction for a period of up to 4 months. Applied locally in the face of people, its effect is a facial rejuvenation that appears within 7-10 days after the toxin is applied, and has a duration of approximately 4 months. Botulin A toxin has been used for the treatment of diseases associated with muscular spasm, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis and urinary bladder relaxation.
  • Botulin A toxin While Botulin A toxin is effective as a facial rejuvenate, it is an enzyme that is inherently unstable. This instability makes its use and handling complicated and less desirable. In fact, it requires freezing before using and must be used within four hours of opening the container. Because it is an enzyme, Botulin A toxin also generates antibodies that prevent its use in consecutive injections and can also induce an allergic response. In addition, its results are delayed 7-10 days, which is undesirable for patients wanting an immediate result. Accordingly, a need exists for a facial rejuvenate that is stable, fast-acting and that is not an enzyme.
  • compositions for interfering with neuronal transmission comprising an effective amount of at least one tricyclic 3,4-propinoperhydropurine are provided.
  • preparations for facial rejuvenation comprise an effective amount of the composition of the invention and a facial cream.
  • FIG. 1 is an illustration of an application pattern for the treatment of a human face.
  • compositions comprising heterocyclic guanidine-type compounds, and more specifically tricyclic 3,4-propinoperhydropurines, can be used for many cosmetic or clinical applications, without any surgery, side effects, allergies, immune rejection or hematoma.
  • the compositions of the invention may be used to treat conditions including, but not limited to blepharospasm, strabismus, focal dystonia, sphinceter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing and facial wrinkling.
  • muscular relaxation is immediate, usually occurring in less than five minutes.
  • compositions of the invention comprise an effective amount of at least one tricyclic 3,4-propinoperhydropurine represented by the following structure:
  • R 1 and R 5 are independently H or OH; R 2 and R 3 are independently H or OSO 3 ; and R 4 is independently COONH 2 , OH, H, COONHSO 3 or COOCH 3 ; and a pharmacologically acceptable carrier.
  • These tricyclic 3,4-propinoperhydropurines may be purified from dinoflagellates, cyanobacterias and also may be accumulated by highly contaminated mollusks, which are also temporary muscular relaxants when locally injected. Any pharmacologically acceptable carrier may be used, including but not limited to water.
  • the compounds of the invention are generally diluted in a solution of acetic acid or 0.09% sodium chloride.
  • an effective amount is that amount sufficient to interfere with neuronal transmission by blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with transmission, paralysing the muscle and preventing it from contracting, or producing a relaxation of contracted muscles.
  • an effective amount of the compositions of the invention may be a 100 to 800 microliter dose of forty units per milliliter solution of tricyclic 3,4-propinoperhydropurines.
  • the unit of activity is the amount of the composition of the invention necessary to block the muscular contractions of the crural biceps of a mouse leg for 1.5 to 2.0 hours.
  • the compounds of the invention are generally diluted with a 10 mM (millimolar), pH 4 solution of acetic acid.
  • the compositions of the invention comprise 40 units per milliliter of a 10 mM, pH 4 solution of acetic acid.
  • the pharmaceutical compositions of the invention comprise Saxitoxin.
  • the pharmaceutical compositions of the invention comprise Gonyautoxin 2.
  • the pharmaceutical compositions of the invention comprise Gonyautoxin 3.
  • the pharmaceutical compositions of the invention comprise Gonyautoxin 4.
  • the pharmaceutical compositions of the invention comprise Gonyautoxin 5.
  • the pharmaceutical compositions of the invention comprise neoSaxtoxin.
  • the pharmaceutical compositions of the invention comprise Gonyautoxin 1.
  • the pharmaceutical compositions of the invention comprise Decarbamoyl-Saxitoxin.
  • TABLE 1 Tricyclic 3,4-propinoperhydropurines Compound R 1 R 2 R 3 R 4 R 5 Saxitoxin H H H COONH 2 OH neoSaxitoxin OH H H COONH 2 OH Decarbamoyl- OH H H OH OH Saxitoxin Gonyautoxin OH H OSO ⁇ 3 COONH 2 OH 1 Gonyautoxin H H OSO ⁇ 3 COONH 2 OH 2 Gonyautoxin H OSO ⁇ 3 H COONH 2 OH 3 Gonyautoxin OH OSO ⁇ 3 H COONH 2 OH 4 Gonyautoxin H H H COONHSO ⁇ 3 OH 5
  • the pharmaceutical compositions comprise a mixture of tricyclic 3,4-propinoperhydropurines.
  • the compounds are purified and used individually and/or mixed together.
  • the pharmaceutical compositions of the invention comprise a mixture of Gonyautoxin 2, Gonyautoxin 3, and Saxitoxin.
  • the pharmaceutical compositions of the invention comprise a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.
  • the pharmaceutical compositions of the invention comprise neoSaxitoxin and Gonyautoxin 2.
  • compositions of the invention comprise a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2. It should be understood by those of skill in the art that other mixtures and combinations of tricyclic 3,4-propinoperhydropurines are within the scope of this invention.
  • the compounds of the invention are used in combination with an effective amount of Botulin A toxin.
  • the pharmaceutical compositions of the invention comprise an effective amount of Botulin A toxin and an effective amount of at least one tricyclic 3,4-propinoperhydropurine.
  • the combination may be used in any cosmetic or clinical application in which the compounds of the invention, or Botulin A toxin are used, for example, blepharospasm, strabismus, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing, and facial wrinkle removal.
  • compositions of the invention may be used for many cosmetic and clinical applications including, but not limited to blepharospasm, strabismus, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing, and facial wrinkle removal.
  • the pharmaceutical compositions of the invention are applied locally in the form of preparations.
  • an effective amount of the pharmaceutical compositions of the invention are added to a facial cream complete with its coadjuvants.
  • these preparations are stable at room temperature, do not require refrigeration, are sterilizable, do not generate antibodies, are not peptide in nature, act immediately, and may be injected repeatedly without any side effects.
  • these compounds when applied locally, these compounds carry out their antispasmodic action by blocking the spreading of nervous impulse, or neuronal transmission, by reversibly binding to the sole biological molecular receptor, i.e. the voltage gated sodium channel, present in all neurons and excitable cells. By binding to this channel, there is no entry of sodium to the neuronal cell; depolarization does not occur and, therefore, propagation of the impulse is stopped.
  • This action mechanism blocks the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralysing the muscle and preventing it from contracting, or producing a relaxation of muscles contracted by pathological problems.
  • This mechanism is particularly efficient for cosmetic purposes, as it does not let some facial muscles contract, all of them associated with and responsible for the formation of wrinkles, thus producing the sought-after effect of facial rejuvenation.
  • the pharmaceutical preparations of the invention are applied locally around the muscle that is to be paralysed or prevented from contracting.
  • the application should be in amounts of no more than one milliliter in different places around the muscle, particularly around the areas of greatest innervations.
  • the unit of activity is the amount of the compositions of the invention necessary to block the contractions of the crural biceps of a mouse leg for 1.5 to 2 hours.
  • the preferred dosage rate is 100 to 800 microliters per injected point, depending on the size, irrigation and anatomical location of the muscle, while maintaining a concentration of 20-40 units/milliliter.
  • the effect is immediately apparent, generally occuring a maximum of thirty seconds after injection. The maximum effect may be seen within 15 minutes.
  • the injection may be accomplished by using a 1 milliliter, tuberculin-type disposable syringe with a twenty-seven to thirty gauge needle. In the case of strabismus, a dose of twenty to forty units in a volume of 50-100 microliters may be injected in the orbicular muscle.
  • Use of the pharmaceutical preparations of the invention is limited to individuals over twelve years old. There is no contraindication for pregnant women.
  • a photographic record is made of the person to be treated, first with her face resting and relaxed, and then, frowning and producing a maximum facial contraction. The person then places ice on their forehead and on the two lateral zones where the preparation is to be injected. With reference to FIG. 2, the application should follow a specific pattern.
  • a volume is injected alongside each black-dot injection point shown in FIG. 2.
  • a pharmaceutical composition comprising a (2:1:1 volume/volume) mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin mixture is applied at a dose of 40 units/milliliter. Each injection is, made with a 1 milliliter, tuberculin-type disposable syringe with a 27-30 gauge needle. After injecting, the point of injection is disinfected with a gauze soaked in bi-alcohol or in any other disinfectant. The total amount required to complete the face treatment is 1.7 milliliters.
  • the expected result is an immediate inability to frown and to show lines when the face is resting.
  • the person experiences a feeling of facial stretching similar to that felt when applying a facial cream mask.
  • ice is applied on the injected zones for five minutes.
  • the patient gets used to the feeling of facial stretching.
  • the person walks out with no discernible wrinkles, a rejuvenated facial look, no face marks or hematoma, and completely normal.
  • the face recovers its normal color within twenty minutes, depending on how relaxed the injected patient has become.
  • the whole application procedure takes ten minutes at the most, and produces a very slight pain from the needle and the injected solution. The pain disappears as soon as the syringe is withdrawn.
  • the patient may be checked the next day and every fifteen days thereafter. At this dose, the effect lasts for one month. After the first month, the treatment may be repeated as often as necessary.

Abstract

Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission are provided.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims priority under the Paris Convention for the Protection of Industrial Property to Chilean Patent Application Number 2764-2001, filed on Nov. 15, 2001 in the Department of Industrial Property in the Republic of Chile. [0001]
    • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • Not applicable. [0002]
    • REFERENCE TO MICROFICHE APPENDIX
  • Not applicable. [0003]
    • FIELD OF THE INVENTION
  • This invention relates to pharmaceutical compositions containing heterocyclic guanidine-type compounds and uses thereof for blocking neuronal transmission. More specifically, this invention relates to tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission. [0004]
    • BACKGROUND OF THE INVENTION
  • The presence of wrinkles in the neck and face of people are seen as negative aesthetic effects by social groups. These marks reflect face aging and increase the subjective awareness of the age of people. Since the beginning of civilization, natural or synthetic chemical compounds have been used and procedures have been developed (i.e. plastic surgery) to alleviate this problem. For example, plastic surgeons and cosmetic centers have been experimenting with and using Botulin A toxin as a pharmaceutical preparation that produces facial rejuvenation by removing face wrinkles. Botulin A toxin is a neurotoxin that acts by chemiodenervation, or blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralysing the muscle and preventing its contraction for a period of up to 4 months. Applied locally in the face of people, its effect is a facial rejuvenation that appears within 7-10 days after the toxin is applied, and has a duration of approximately 4 months. Botulin A toxin has been used for the treatment of diseases associated with muscular spasm, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis and urinary bladder relaxation. [0005]
  • While Botulin A toxin is effective as a facial rejuvenate, it is an enzyme that is inherently unstable. This instability makes its use and handling complicated and less desirable. In fact, it requires freezing before using and must be used within four hours of opening the container. Because it is an enzyme, Botulin A toxin also generates antibodies that prevent its use in consecutive injections and can also induce an allergic response. In addition, its results are delayed 7-10 days, which is undesirable for patients wanting an immediate result. Accordingly, a need exists for a facial rejuvenate that is stable, fast-acting and that is not an enzyme. [0006]
    • SUMMARY OF THE INVENTION
  • In accordance with the objects of the invention, novel compositions and methods are provided. In one aspect of the invention, pharmaceutical compositions for interfering with neuronal transmission comprising an effective amount of at least one tricyclic 3,4-propinoperhydropurine are provided. [0007]
  • In a second aspect of the invention, preparations for facial rejuvenation are provided that comprise an effective amount of the composition of the invention and a facial cream. [0008]
  • In a third aspect of the invention, methods of interfering with neuronal transmission comprising contacting a neuron with an effective amount of the pharmaceutical compositions of the invention are provided. [0009]
  • In a forth aspect of the invention, methods of interfering with muscle contracting comprising contacting a muscle with an effective amount of the composition of the invention are provided.[0010]
    • DETAILED DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is an illustration of an application pattern for the treatment of a human face.[0011]
    • DETAILED DESCRIPTION OF THE INVENTION
  • In accordance with the present invention, it has been discovered that compositions comprising heterocyclic guanidine-type compounds, and more specifically tricyclic 3,4-propinoperhydropurines, can be used for many cosmetic or clinical applications, without any surgery, side effects, allergies, immune rejection or hematoma. The compositions of the invention may be used to treat conditions including, but not limited to blepharospasm, strabismus, focal dystonia, sphinceter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing and facial wrinkling. In accordance with the present invention, muscular relaxation is immediate, usually occurring in less than five minutes. [0012]
  • The compositions of the invention comprise an effective amount of at least one tricyclic 3,4-propinoperhydropurine represented by the following structure: [0013]
    Figure US20030100574A1-20030529-C00001
  • wherein R[0014] 1 and R5 are independently H or OH; R2 and R3 are independently H or OSO3; and R4 is independently COONH2, OH, H, COONHSO3 or COOCH3; and a pharmacologically acceptable carrier. These tricyclic 3,4-propinoperhydropurines may be purified from dinoflagellates, cyanobacterias and also may be accumulated by highly contaminated mollusks, which are also temporary muscular relaxants when locally injected. Any pharmacologically acceptable carrier may be used, including but not limited to water. The compounds of the invention are generally diluted in a solution of acetic acid or 0.09% sodium chloride.
  • As used herein, “an effective amount” is that amount sufficient to interfere with neuronal transmission by blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with transmission, paralysing the muscle and preventing it from contracting, or producing a relaxation of contracted muscles. For example, an effective amount of the compositions of the invention may be a 100 to 800 microliter dose of forty units per milliliter solution of tricyclic 3,4-propinoperhydropurines. The unit of activity is the amount of the composition of the invention necessary to block the muscular contractions of the crural biceps of a mouse leg for 1.5 to 2.0 hours. The compounds of the invention are generally diluted with a 10 mM (millimolar), pH 4 solution of acetic acid. In one specific embodiment of the invention, the compositions of the invention comprise 40 units per milliliter of a 10 mM, pH 4 solution of acetic acid. [0015]
  • In one embodiment of the invention, and with reference to Table 1 below, the pharmaceutical compositions of the invention comprise Saxitoxin. In a second embodiment of the invention, the pharmaceutical compositions of the invention comprise Gonyautoxin 2. In a third embodiment of the invention, the pharmaceutical compositions of the invention comprise Gonyautoxin 3. In a forth embodiment of the invention, the pharmaceutical compositions of the invention comprise Gonyautoxin 4. In a fifth embodiment of the invention, the pharmaceutical compositions of the invention comprise Gonyautoxin 5. In a sixth embodiment of the invention, the pharmaceutical compositions of the invention comprise neoSaxtoxin. In a seventh embodiment of the invention, the pharmaceutical compositions of the invention comprise Gonyautoxin 1. In an eighth embodiment of the invention, the pharmaceutical compositions of the invention comprise Decarbamoyl-Saxitoxin. [0016]
    TABLE 1
    Tricyclic 3,4-propinoperhydropurines
    Compound R1 R2 R3 R4 R5
    Saxitoxin H H H COONH2 OH
    neoSaxitoxin OH H H COONH2 OH
    Decarbamoyl- OH H H OH OH
    Saxitoxin
    Gonyautoxin OH H OSO− 3 COONH2 OH
    1
    Gonyautoxin H H OSO− 3 COONH2 OH
    2
    Gonyautoxin H OSO− 3 H COONH2 OH
    3
    Gonyautoxin OH OSO− 3 H COONH2 OH
    4
    Gonyautoxin H H H COONHSO− 3 OH
    5
  • In specific embodiments of the invention, the pharmaceutical compositions comprise a mixture of tricyclic 3,4-propinoperhydropurines. The compounds are purified and used individually and/or mixed together. In one preferred embodiment, the pharmaceutical compositions of the invention comprise a mixture of Gonyautoxin 2, Gonyautoxin 3, and Saxitoxin. In another preferred embodiment, the pharmaceutical compositions of the invention comprise a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2. In yet another preferred embodiment, the pharmaceutical compositions of the invention comprise neoSaxitoxin and Gonyautoxin 2. In still another preferred embodiment, the pharmaceutical compositions of the invention comprise a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2. It should be understood by those of skill in the art that other mixtures and combinations of tricyclic 3,4-propinoperhydropurines are within the scope of this invention. [0017]
  • In one embodiment of the invention, the compounds of the invention are used in combination with an effective amount of Botulin A toxin. In this embodiment, the pharmaceutical compositions of the invention comprise an effective amount of Botulin A toxin and an effective amount of at least one tricyclic 3,4-propinoperhydropurine. The combination may be used in any cosmetic or clinical application in which the compounds of the invention, or Botulin A toxin are used, for example, blepharospasm, strabismus, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing, and facial wrinkle removal. [0018]
  • These pharmaceutical compositions of the invention may be used for many cosmetic and clinical applications including, but not limited to blepharospasm, strabismus, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing, and facial wrinkle removal. Generally, the pharmaceutical compositions of the invention are applied locally in the form of preparations. To form preparations, an effective amount of the pharmaceutical compositions of the invention are added to a facial cream complete with its coadjuvants. Unlike Botulin A toxin, these preparations are stable at room temperature, do not require refrigeration, are sterilizable, do not generate antibodies, are not peptide in nature, act immediately, and may be injected repeatedly without any side effects. [0019]
  • Without being bound by theory, when applied locally, these compounds carry out their antispasmodic action by blocking the spreading of nervous impulse, or neuronal transmission, by reversibly binding to the sole biological molecular receptor, i.e. the voltage gated sodium channel, present in all neurons and excitable cells. By binding to this channel, there is no entry of sodium to the neuronal cell; depolarization does not occur and, therefore, propagation of the impulse is stopped. This action mechanism blocks the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralysing the muscle and preventing it from contracting, or producing a relaxation of muscles contracted by pathological problems. This mechanism is particularly efficient for cosmetic purposes, as it does not let some facial muscles contract, all of them associated with and responsible for the formation of wrinkles, thus producing the sought-after effect of facial rejuvenation. [0020]
  • The pharmaceutical preparations of the invention are applied locally around the muscle that is to be paralysed or prevented from contracting. The application should be in amounts of no more than one milliliter in different places around the muscle, particularly around the areas of greatest innervations. The unit of activity is the amount of the compositions of the invention necessary to block the contractions of the crural biceps of a mouse leg for 1.5 to 2 hours. The preferred dosage rate is 100 to 800 microliters per injected point, depending on the size, irrigation and anatomical location of the muscle, while maintaining a concentration of 20-40 units/milliliter. The effect is immediately apparent, generally occuring a maximum of thirty seconds after injection. The maximum effect may be seen within 15 minutes. Its effective duration depends on the dose administered, the muscle in question, as well as the volume and specific composition administered. This is the pattern for all clinical applications and pathologies. The injection may be accomplished by using a 1 milliliter, tuberculin-type disposable syringe with a twenty-seven to thirty gauge needle. In the case of strabismus, a dose of twenty to forty units in a volume of 50-100 microliters may be injected in the orbicular muscle. Use of the pharmaceutical preparations of the invention is limited to individuals over twelve years old. There is no contraindication for pregnant women. [0021]
  • The advantageous properties of this invention can be observed by reference to the following example, which is meant to illustrate, and not limit, the invention in any way. [0022]
    • EXAMPLE
  • Before the application, a photographic record is made of the person to be treated, first with her face resting and relaxed, and then, frowning and producing a maximum facial contraction. The person then places ice on their forehead and on the two lateral zones where the preparation is to be injected. With reference to FIG. 2, the application should follow a specific pattern. A volume is injected alongside each black-dot injection point shown in FIG. 2. A pharmaceutical composition comprising a (2:1:1 volume/volume) mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin mixture is applied at a dose of 40 units/milliliter. Each injection is, made with a 1 milliliter, tuberculin-type disposable syringe with a 27-30 gauge needle. After injecting, the point of injection is disinfected with a gauze soaked in bi-alcohol or in any other disinfectant. The total amount required to complete the face treatment is 1.7 milliliters. [0023]
  • The expected result is an immediate inability to frown and to show lines when the face is resting. The person experiences a feeling of facial stretching similar to that felt when applying a facial cream mask. After that, ice is applied on the injected zones for five minutes. Thirty minutes after the application, the patient gets used to the feeling of facial stretching. At that time, the person walks out with no discernible wrinkles, a rejuvenated facial look, no face marks or hematoma, and completely normal. The face recovers its normal color within twenty minutes, depending on how relaxed the injected patient has become. The whole application procedure takes ten minutes at the most, and produces a very slight pain from the needle and the injected solution. The pain disappears as soon as the syringe is withdrawn. There are no traumas of any kind, nor any sequelae. The patient may be checked the next day and every fifteen days thereafter. At this dose, the effect lasts for one month. After the first month, the treatment may be repeated as often as necessary. [0024]
  • In view of the above, it will be seen that all the objects and features of the present invention are achieved, and other advantageous results obtained. The examples and description of the invention contained herein is illustrative only, and is not intended in a limiting sense. [0025]

Claims (47)

What is claimed:
1. A pharmaceutical composition for interfering with neuronal transmission, the composition comprising an effective amount of at least one compound represented by the following structure:
Figure US20030100574A1-20030529-C00002
wherein R1 and R5 are independently H or OH; R2 and R3 are independently H or OSO3; and R4 is independently COONH2, OH, H, COONHSO3 or COOCH3; and a pharmacologically acceptable carrier.
2. The composition of claim 1, wherein the composition comprises a mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin.
3. The composition of claim 1, wherein the composition comprises a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.
4. The composition of claim 1, wherein the composition comprises a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2.
5. The composition of claim 1, further comprising Botulin A toxin.
6. The composition of claim 1, wherein the carrier is water.
7. The composition of claim 1, wherein the carrier is 0.09% Sodium Chloride.
8. The composition of claim 1, wherein the composition comprises about twenty to about forty units of the compound per milliliter of total solution.
9. The composition of claim 8, wherein the composition comprises forty units of the compound per milliliter of total solution.
10. The composition of claim 1, wherein the compound is diluted in a solution of acetic acid.
11. A preparation for facial rejuvenation comprising an effective amount of the composition of claim 1 and a facial cream.
12. The preparation of claim 11, wherein said composition comprises about twenty to about forty units of the compound per milliliter of total solution.
13. The preparation of claim 11, wherein said composition comprises about forty units of the compound per milliliter of total solution.
14. The preparation of claim 11, wherein said carrier is water.
15. The preparation of claim 11, wherein said compound is diluted in a solution of acetic acid.
16. The preparation of claim 11, wherein the composition comprises a mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin.
17. The preparation of claim 11, wherein the composition comprises a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2.
18. The preparation of claim 11 wherein the composition comprises a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.
19. The preparation of claim 11, further comprising Botulin A toxin.
20. A method of interfering with neuronal transmission comprising contacting a neuron with an effective amount of the composition of claim 1.
21. The method of claim 20, wherein the composition comprises a mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin.
22. The method of claim 20, wherein the composition comprises a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2.
23. The method of claim 20, wherein the composition comprises a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.
24. The method of claim 20, wherein the composition further comprises Botulin A toxin.
25. The method of claim 20, wherein about 100 to about 800 microliters of said composition is contacted with said neuron.
26. The method of claim 20, wherein less than one milliliter of said composition is contacted with said neuron.
27. The method of claim 20, wherein contacting an effective amount of the composition of claim 1 with a neuron comprises injecting the composition of claim 1 in an area proximate to the neuron.
28. The method of claim 20, wherein said composition comprises about forty units of the compound per milliliter of total solution.
29. The method of claim 20, wherein said composition comprises about 20 to about 40 units of the compound per milliliter of total solution.
30. The method of claim 20, wherein said compound is diluted in a solution of acetic acid.
31. The method of claim 20, wherein said neuron is in a muscle.
32. The method of claim 31, wherein said muscle is inside a human face.
33. A method interfering with muscle contraction comprising contacting a muscle with an effective amount of the composition of claim 1.
34. The method of claim 33, wherein the composition of claim 1 comprises a mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin.
35. The method of claim 33, wherein the composition of claim 1 comprises a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2.
36. The method of claim 33, wherein the composition of claim 1 comprises a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.
37. The method of claim 33, wherein the composition of claim 1 further comprises Botulin A toxin.
38. The method of claim 33, wherein the composition of claim 1 comprises about 20 to about 40 units of the compound per milliliter of the carrier.
39. The method of claim 33, wherein the carrier is acetic acid.
40. The method of claim 33, wherein the composition of claim 1 comprises about twenty to about forty units of the compound per milliliter of total solution.
41. The method of claim 33, wherein the composition of claim 1 comprises about forty units of the compound per milliliter of total solution.
42. The method of claim 33, wherein contacting an effective amount of the composition of claim 1 with a muscle comprises injecting the composition into an area proximate to the muscle.
43. The method of claim 42, wherein no more than one milliliter of the composition of claim 1 is injected into an area proximate to the muscle per injection point.
44. The method of claim 42, wherein about 100 to about 800 microliters of the composition of claim 1 is injected into an area proximate to the muscle per injection point.
45. The method of claim 33, wherein the muscle is inside a human face.
46. The method of claim 33, wherein the carrier is 0.09% sodium chloride.
47. The method of claim 33, wherein the compound is diluted in a solution of acetic acid.
US10/294,288 2001-11-15 2002-11-14 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies Abandoned US20030100574A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/338,156 US20060122200A1 (en) 2001-11-15 2006-01-24 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
US13/487,722 US9301958B2 (en) 2001-11-15 2012-06-04 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine
US14/043,634 US8889681B2 (en) 2001-11-15 2013-10-01 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US14/249,914 US8871763B2 (en) 2001-11-15 2014-04-10 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2764-2001 2001-11-15
CL27642001 2001-11-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/338,156 Division US20060122200A1 (en) 2001-11-15 2006-01-24 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies

Publications (1)

Publication Number Publication Date
US20030100574A1 true US20030100574A1 (en) 2003-05-29

Family

ID=4574581

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/294,288 Abandoned US20030100574A1 (en) 2001-11-15 2002-11-14 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US11/338,156 Abandoned US20060122200A1 (en) 2001-11-15 2006-01-24 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
US13/487,722 Expired - Lifetime US9301958B2 (en) 2001-11-15 2012-06-04 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine
US14/043,634 Expired - Fee Related US8889681B2 (en) 2001-11-15 2013-10-01 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US14/249,914 Expired - Fee Related US8871763B2 (en) 2001-11-15 2014-04-10 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies

Family Applications After (4)

Application Number Title Priority Date Filing Date
US11/338,156 Abandoned US20060122200A1 (en) 2001-11-15 2006-01-24 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
US13/487,722 Expired - Lifetime US9301958B2 (en) 2001-11-15 2012-06-04 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine
US14/043,634 Expired - Fee Related US8889681B2 (en) 2001-11-15 2013-10-01 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US14/249,914 Expired - Fee Related US8871763B2 (en) 2001-11-15 2014-04-10 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies

Country Status (18)

Country Link
US (5) US20030100574A1 (en)
EP (1) EP1443932B1 (en)
JP (2) JP5331959B2 (en)
KR (2) KR20100135884A (en)
CN (2) CN1585642A (en)
AU (1) AU2002348370B8 (en)
BR (1) BR0214126A (en)
CA (1) CA2466697C (en)
EA (1) EA006739B1 (en)
ES (1) ES2401570T3 (en)
HU (1) HUP0402268A2 (en)
IL (1) IL161949A0 (en)
MX (1) MXPA04004543A (en)
NO (1) NO20042475L (en)
NZ (1) NZ533309A (en)
PL (1) PL370686A1 (en)
WO (1) WO2003047589A1 (en)
ZA (1) ZA200403765B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110417A1 (en) 2004-05-07 2005-11-24 Phytotox Limited Phycotoxins and uses thereof
WO2005110418A2 (en) 2004-05-07 2005-11-24 Phytotox Limited Transdermal administration of phycotoxins
WO2006119499A3 (en) * 2005-05-05 2006-12-28 Phytotox Ltd Use of phycotoxins in veterinary applications
WO2010109386A1 (en) * 2009-03-24 2010-09-30 Proteus S.A. Method for the industrial purification of biologically active phycotoxins
WO2011098539A1 (en) * 2010-02-10 2011-08-18 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives
US10920256B2 (en) 2016-02-12 2021-02-16 Vestlandets Innovasjonsseiskap AS Process

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1443932B1 (en) * 2001-11-15 2012-12-26 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
JP2009177044A (en) * 2008-01-28 2009-08-06 Panasonic Corp Electrical fuse circuit
CN102459273A (en) * 2009-05-07 2012-05-16 里兰斯坦福初级大学理事会 Methods and compositions for studying, imaging, and treating pain
CA2906851C (en) 2013-03-15 2019-05-07 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957966A (en) * 1972-05-19 1976-05-18 Gaf Corporation Stabilized vitamin food coatings
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5714468A (en) * 1994-05-09 1998-02-03 Binder; William J. Method for reduction of migraine headache pain
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US5908746A (en) * 1995-06-09 1999-06-01 Nisshinbo Industries, Inc. Method for analyzing biologically active substances
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
US6117877A (en) * 1998-02-27 2000-09-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6187756B1 (en) * 1996-09-05 2001-02-13 The Massachusetts Institute Of Technology Composition and methods for treatment of neurological disorders and neurodegenerative diseases
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20010046962A1 (en) * 1991-09-24 2001-11-29 Allergan Inc. Method and compositions for the treatment of cerebral palsy
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
US20010053369A1 (en) * 2000-06-14 2001-12-20 Stephen Donovan Epilepsy treatment
US20010053390A1 (en) * 1999-07-14 2001-12-20 Kaijun Ren Use of plant extracts for treatment of acne and furuncle
US20020025327A1 (en) * 1997-07-15 2002-02-28 University Technology Corporation Use of neurotoxin therapy for treatment of urologic and related disorders
US6358926B2 (en) * 1999-10-13 2002-03-19 Allergan Sales, Inc. Neurotoxin therapy for inner ear disorders
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US6416765B1 (en) * 2000-01-11 2002-07-09 Allergan Sales, Inc. Neurotoxin therapy for diabetes
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6447787B1 (en) * 1998-10-27 2002-09-10 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US20020161013A1 (en) * 2001-04-25 2002-10-31 Wex Medical Intrumentation Co., Ltd. Method of local anesthesia and analgesia
US20020176872A1 (en) * 2000-04-14 2002-11-28 Allergan Sales, Inc. Pain treatment by peripheral administration of a neurotoxin
US20020192240A1 (en) * 2000-10-04 2002-12-19 Allergan Sales, Inc. Therapy for injured muscles
US20020198226A1 (en) * 2001-05-18 2002-12-26 Baoshan Ku Analgesic composition and method
US6599906B1 (en) * 2000-09-18 2003-07-29 Wex Medical Instrumentation Co., Ltd. Method of local anesthesia and analgesia
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029794A (en) * 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition
US4001413A (en) * 1973-06-12 1977-01-04 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition employing saxitoxin
JP3359193B2 (en) * 1995-07-21 2002-12-24 キヤノン株式会社 Exposure apparatus and device manufacturing method using the same
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
CN1081034C (en) * 1997-03-07 2002-03-20 潘心富 Medicine of diguanidino-prine-hydride compounds for giving up drug-taking
WO2001036588A2 (en) * 1999-11-16 2001-05-25 The General Hospital Corporation Fusion proteins that specifically inhibit protein synthesis in neuronal cells
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
CN1284536C (en) * 2000-09-18 2006-11-15 威克斯医药有限公司 Antalgic method by general medicine application
CN1240702C (en) 2000-09-18 2006-02-08 威克斯医药有限公司 Process for extracting tetrodosin with high output rate
CN1236773C (en) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 Preparation for analgesia and anesthesia or curing drug dependence
EP1443932B1 (en) * 2001-11-15 2012-12-26 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
CN1194693C (en) * 2002-01-11 2005-03-30 中国科学院海洋研究所 Application of paralytic PSP toxin in preparing antalgesic medicine

Patent Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957966A (en) * 1972-05-19 1976-05-18 Gaf Corporation Stabilized vitamin food coatings
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5298019A (en) * 1990-08-21 1994-03-29 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US20010046962A1 (en) * 1991-09-24 2001-11-29 Allergan Inc. Method and compositions for the treatment of cerebral palsy
US20020142010A1 (en) * 1991-09-24 2002-10-03 Allergan Method and compositions for the treatment of cerebral palsy
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5674205A (en) * 1993-08-26 1997-10-07 The Johns Hopkins University Device for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5714468A (en) * 1994-05-09 1998-02-03 Binder; William J. Method for reduction of migraine headache pain
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
US5908746A (en) * 1995-06-09 1999-06-01 Nisshinbo Industries, Inc. Method for analyzing biologically active substances
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US6187756B1 (en) * 1996-09-05 2001-02-13 The Massachusetts Institute Of Technology Composition and methods for treatment of neurological disorders and neurodegenerative diseases
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
US20020025327A1 (en) * 1997-07-15 2002-02-28 University Technology Corporation Use of neurotoxin therapy for treatment of urologic and related disorders
US6432986B2 (en) * 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US6117877A (en) * 1998-02-27 2000-09-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6447787B1 (en) * 1998-10-27 2002-09-10 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US20030036502A1 (en) * 1998-10-27 2003-02-20 Gassner Holger G. Methods for enhancing wound healing
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US20010053390A1 (en) * 1999-07-14 2001-12-20 Kaijun Ren Use of plant extracts for treatment of acne and furuncle
US6358926B2 (en) * 1999-10-13 2002-03-19 Allergan Sales, Inc. Neurotoxin therapy for inner ear disorders
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6416765B1 (en) * 2000-01-11 2002-07-09 Allergan Sales, Inc. Neurotoxin therapy for diabetes
US20020176872A1 (en) * 2000-04-14 2002-11-28 Allergan Sales, Inc. Pain treatment by peripheral administration of a neurotoxin
US20040018213A1 (en) * 2000-04-14 2004-01-29 Allergan Inc. Pain treatment by peripheral administration of a neurotoxin
US20040028706A1 (en) * 2000-04-14 2004-02-12 Aoki Kei Roger Neuralgia pain treatment by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20010053369A1 (en) * 2000-06-14 2001-12-20 Stephen Donovan Epilepsy treatment
US6599906B1 (en) * 2000-09-18 2003-07-29 Wex Medical Instrumentation Co., Ltd. Method of local anesthesia and analgesia
US20020192240A1 (en) * 2000-10-04 2002-12-19 Allergan Sales, Inc. Therapy for injured muscles
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US20020161013A1 (en) * 2001-04-25 2002-10-31 Wex Medical Intrumentation Co., Ltd. Method of local anesthesia and analgesia
US20020198226A1 (en) * 2001-05-18 2002-12-26 Baoshan Ku Analgesic composition and method
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1824488A4 (en) * 2004-05-07 2008-07-02 Phytotox Ltd Phycotoxins and uses thereof
AU2005244116B8 (en) * 2004-05-07 2011-03-31 Algenis Spa Methods of treating wounds with gonyautoxins
WO2005110418A2 (en) 2004-05-07 2005-11-24 Phytotox Limited Transdermal administration of phycotoxins
EP1796676A4 (en) * 2004-05-07 2008-06-25 Phytotox Ltd Transdermal administration of phycotoxins
EP1796676A2 (en) * 2004-05-07 2007-06-20 Phytotox Limited Transdermal administration of phycotoxins
EP1802250A1 (en) * 2004-05-07 2007-07-04 Phytotox Limited Methods of treating wounds with gonyautoxins
EP1824488A1 (en) * 2004-05-07 2007-08-29 Phytotox Limited Phycotoxins and uses thereof
US20070280970A1 (en) * 2004-05-07 2007-12-06 Phytotox Limited Methods of Treating Wounds With Gonyautoxins
US20080021051A1 (en) * 2004-05-07 2008-01-24 Phytotox Limited Phycotoxins and Uses Thereof
US20080045553A1 (en) * 2004-05-07 2008-02-21 Phytotox Limited Transdermal Administration of Phycotoxins
EP1802250A4 (en) * 2004-05-07 2008-07-02 Phytotox Ltd Methods of treating wounds with gonyautoxins
US8377951B2 (en) 2004-05-07 2013-02-19 Phytotox Limited Transdermal administration of phycotoxins
AU2005244116B2 (en) * 2004-05-07 2011-03-03 Algenis Spa Methods of treating wounds with gonyautoxins
AU2005244105B2 (en) * 2004-05-07 2011-10-06 Algenis Spa Phycotoxins and uses thereof
WO2005110417A1 (en) 2004-05-07 2005-11-24 Phytotox Limited Phycotoxins and uses thereof
AU2005244096B2 (en) * 2004-05-07 2011-03-17 Algenis Spa Transdermal administration of phycotoxins
WO2005110275A1 (en) 2004-05-07 2005-11-24 Phytotox Limited Methods of treating wounds with gonyautoxins
AU2005244116C1 (en) * 2004-05-07 2011-09-29 Algenis Spa Methods of treating wounds with gonyautoxins
WO2006119499A3 (en) * 2005-05-05 2006-12-28 Phytotox Ltd Use of phycotoxins in veterinary applications
WO2010109386A1 (en) * 2009-03-24 2010-09-30 Proteus S.A. Method for the industrial purification of biologically active phycotoxins
WO2011098539A1 (en) * 2010-02-10 2011-08-18 Phytotox Limited Treatment of loss of sense of touch with saxitoxin derivatives
US9107925B2 (en) 2010-02-10 2015-08-18 Phytotox Limited Sodium channel blocker for treatment of loss of superficial sensitivity
US11566271B2 (en) 2016-02-12 2023-01-31 Vestlandets Innovasjonsseiskap AS Processes to make neosaxitoxin and analogues thereof
US10920256B2 (en) 2016-02-12 2021-02-16 Vestlandets Innovasjonsseiskap AS Process

Also Published As

Publication number Publication date
CN102349914B (en) 2015-01-28
CN102349914A (en) 2012-02-15
PL370686A1 (en) 2005-05-30
IL161949A0 (en) 2005-11-20
EA200400670A1 (en) 2004-10-28
US20140221407A1 (en) 2014-08-07
HUP0402268A2 (en) 2005-02-28
EP1443932B1 (en) 2012-12-26
EP1443932A1 (en) 2004-08-11
CA2466697A1 (en) 2003-06-12
US20120238592A1 (en) 2012-09-20
AU2002348370A1 (en) 2003-06-17
JP5331959B2 (en) 2013-10-30
US20140163051A1 (en) 2014-06-12
WO2003047589A8 (en) 2004-06-24
JP2005515203A (en) 2005-05-26
NZ533309A (en) 2006-03-31
US8889681B2 (en) 2014-11-18
US9301958B2 (en) 2016-04-05
KR20040066816A (en) 2004-07-27
EP1443932A4 (en) 2007-11-28
MXPA04004543A (en) 2005-03-31
US20060122200A1 (en) 2006-06-08
JP2011068649A (en) 2011-04-07
AU2002348370B2 (en) 2008-04-17
CA2466697C (en) 2013-09-24
BR0214126A (en) 2004-10-13
NO20042475L (en) 2004-06-14
WO2003047589A1 (en) 2003-06-12
KR20100135884A (en) 2010-12-27
AU2002348370B8 (en) 2008-05-01
US8871763B2 (en) 2014-10-28
ZA200403765B (en) 2005-07-27
EA006739B1 (en) 2006-04-28
ES2401570T3 (en) 2013-04-22
CN1585642A (en) 2005-02-23

Similar Documents

Publication Publication Date Title
US8889681B2 (en) Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies
US6197830B1 (en) Method for achieving relief from sympathetically mediated pain
AU2005244096B2 (en) Transdermal administration of phycotoxins
AU2005227192A1 (en) Compositions and methods for preventing and treating skin and hair conditions
EP2977058A1 (en) Methods for treating adhesive capsulitis
EP2533785A1 (en) Treatment of loss of sense of touch with saxitoxin derivatives
RU2289417C1 (en) Method for biological skin rejuvenation
WO2014204090A1 (en) Composition comprising filler and botulinum toxin for alleviating skin wrinkles or aging or treating neuromuscular diseases
EP1135094B1 (en) Method to reduce hair loss and stimulate hair regrowth
CA2356543A1 (en) Process and composition for improving the growth of human head hair
Matthews-Brzozowska et al. Mesotherapy–a method of facial skin rejuvenation from an interdisciplinary perspective on improving facial aesthetics
BRPI0214126B1 (en) Pharmaceutical composition for interfering with neuronal transmission, and preparation for facial rejuvenation
US5176912A (en) Method of treating psoriasis
Wirtschafter et al. Botulinum toxin injections for treatment of blepharospasm and hemifacial spasm
Bernard et al. Randomized, open-labelled comparison between an idoxuridine 10% gel and acyclovir 5% cream in recurrent herpes labialis.
Andre An easy and effective local anaesthesia for treating palmar hyperhidrosis with botulinum toxin injections: the Cry-ac system.
Herron et al. Eyelid Ptosis following Botulinum a Exotoxin Injections Reversed with Apraclonidine
JPS60208907A (en) Hair growth stimulant
West properly and after being worn for days, are unlikely to prove disturbing. They do not interfere with ordinary con¬
KR20000063326A (en) A liquid medicine with surface anesthesia effect

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHYTOTOX S.A., CHILE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WILSON, NESTOR ANTONIO LAGOS;REEL/FRAME:013686/0331

Effective date: 20021114

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION